Özcan Met, Associate Professor and Head of Cell Therapy Unit at National Center for Cancer Immune Therapy, posted on LinkedIn:
“This week, the first patient with melanoma received TILs edited with non-viral CRISPR technology – a truly exciting step forward in cell therapy! As someone deeply involved in academic ATMP development, moments like this a powerful reminder of why we do what we do!
Academic trials play a crucial role in bringing innovative therapies from the lab to the clinic, often paving the way for future breakthroughs. They allow us to explore cutting-edge technologies, refine our approaches, and most importantly, offer new hope to patients.
Well done team!”